Interleukin-28A (IL-28A) modulates CD11c+ dendritic cell (DC) function and promotes type 1T helper (Th1) differentiation, thus suppressing allergic airway diseases. However, the function of the IL-28A isoform IL-28B in these diseases remains largely unknown. In this study, we revealed a novel role of IL-28B in inducing type 1 immunity and protecting against ovalbumin (OVA)-induced allergic asthma in mice. IL-28B overexpression in wild-type mice promoted natural killer (NK) cell polarization in the lung, leading to the increased number of interferon (IFN)-γ-producing NK1 cells as well as Th1 differentiation. Importantly, IL-28B overexpression had no protective effect on OVA-induced asthma in IFN-γ-knockout (IFN-γ−/−) mice. These results demonstrate that IL-28B ameliorates experimental allergic asthma via enhancing NK cell polarization, which might be useful for prevention and treatment of allergic asthma.
a heterodimeric receptor consisting of IL-28Rα and IL-10Rβ 17 . Among them, IL-10Rβ is ubiquitously expressed and shared with all other IL-10 family members. In contrast, IL-28Rα is expressed on epithelium-derived cells like hepatocytes and myeloid lineage cells, such as dendritic cells (DCs) and macrophages 18, 19 , and are responsible for ligand specificity. Recently, human and mouse NK cells were found to also express IL-28Rα 20 . Previous study demonstrated that IL-28A suppresses allergic airway disease through modulating lung DC function and promoting Th1 differentiation 16 . In the present study, we found that IL-28B could increase the frequency and number of NK cells in OVA-challenged mouse lung, which prompts us to investigate the role of IL-28B in OVA-induced airway inflammation and the underlying mechanisms. As we demonstrated, IL-28B promoted NK1 cell polarization in vivo and suppressed OVA-induced allergic asthma in mice, suggesting NK cells are potential immunotherapeutic agents.
Materials and Methods
Animals. All The effect of plive-IL-28B on the airway resistance in the mouse lung. (I) Histological assessment of lung inflammation in PBS-, plive-vector-or plive-IL28B-treated asthmatic mice. (J) PAS staining for mucus production in lung epithelium of PBS-, plive-vector-or plive-IL28B-treated asthmatic mice. PBS is phosphate buffer saline. OVA is ovalbumin. Alum is aluminum. BALF is bronchoalveolar lavage fluid. I.V. is intravenous injection. i.p. is intraperitoneal injection. i.n. is nasal inhalation. mAch is muscarinic acetylcholine. PAS is Periodic Acid-Schiff stain. H&E is hematoxylin-eosin staining. *p < 0.05; **p < 0.01; ***p < 0.001; ns: non-significant (n = 5 mice per group). Results shown are representative of three independent experiments.
Scientific RepoRts | 7: 3556 | DOI:10.1038/s41598-017-03856-w from Shanghai SLAC Laboratory Animal center, Chinese Academy Science (Shanghai, China). IFN-γ−/− mice on a C57BL/6 genetic background were kindly provided by Dr. Shaobo Su (Tongji University School of Medicine, Shanghai, China). All mice were housed in micro-isolator cages under humidity-and temperature-controlled specific pathogen-free condition in the animal facility of the School of Life of USTC.
Antibodies and recombinant plive vectors. AsGM1 Antibody was purchased from Wako Co., Ltd.
(Tokyo, Japan). The plive vector is a kind of liver-specific transgene expression vector which utilizes a chimeric promoter composed of the minimal mouse albumin promoter and mouse alpha fetoprotein enhancer II. Recombinant plive vector expressing IL-28B (plive-IL-28B) was kindly provided by Dr. Yanshi Wang at USTC, and was amplified using the EndoFree Maxi plasmid kit (Macherey-Nagel, Duren, Germany). OVA was purchased from Sigma-Aldrich (St. Louis, MO, USA). Aluminum adjuvant was purchased from Thermo Fisher Scientific (Rockford, IL, USA).
Cytokine Detection. IL-28B were detected using mouse IL-28 platinum ELISA Kit (eBioscience, CA, USA) according to the manufacturer's instructions.
Measurement of IgE in serum.
The mouse sera were isolated and frozen at −80 °C before use. The concentrations of total IgE in serum were determined using the Mouse IgE ELISA kits (Dakewe Biotech Co., Ltd., Shenzhen, China), following the manufacturer's instructions.
Hydrodynamic injection. The plive-IL-28B was purified using the EndoFree Maxi plasmid kit (Macherey-Nagel, Duren, Germany). 20 mg of purified plive-IL-28B dissolved in PBS in a volume equivalent to 8% of the mouse body weight was injected via tail veins within 5 seconds on day 1 as indicated in the experimental protocol. The same dose of null plive-vector and equivalent volume of PBS were given as control respectively.
Allergen sensitization and challenge protocol and treatment regimens. All mice were sensitized with two intraperitoneal injections on days 0 and 7 of 100 μg OVA (Grade V; Sigma-Aldrich, St. Louis, MO, USA) complexed with 50 μL adjuvant aluminum hydroxide (Thermo Fisher Scientific, Rockford, IL, USA). On days 14, 15 and 16, mice were administered intranasally with 50 μg OVA in a volume of 50 μL.
In vivo depletion of NK cells. To deplete NK cells 21 , mice were administered anti-asialo GM1 Ab (AsGM1) (50 μL/mouse, i.v.; Wako Pure Chemical Industries, Ltd., Japan) 22 or control IgG (Rabbit) 1 day before OVA challenges indicated in the experimental protocol.
Collection and analysis of the BALF. 24 h after the last OVA challenge, BALF was obtained by rinsing lungs followed by centrifugation with 0.8 mL PBS at 1500 rpm for 5 min. The supernatants were analyzed by ELISA, and the pellets were washed three times with 1.0 mL PBS followed by centrifugation at 1500 rpm for additional 5 min. All cell pellets were suspended in 1.0 mL PBS. 
Isolation of lymphocytes.
Mice were anesthetized, then lungs were collected, excised and minced, followed digestion for 60 min at 37° with RPMI-1640 containing 0.1% collagenase IV (Sigma, St Louis, MO) and 5% fetal calf serum. The large pieces of lung were removed by filtration through gauze. The residual RBCs were lysed with RBC lysis buffer (Biolegend, San Diego, CA, USA). The resultant single cell suspensions were washed three times with ice cold PBS. Cell numbers were determined by trypan blue exclusion method.
Histological analysis. Lung tissues were fixed in 10% (vol/vol) neutral buffered formalin and embedded in paraffin. Sections (5 µm) were stained with hematoxylin/eosin (H&E) or periodic acid-Schiff 's (PAS) solution (Sigma-Aldrich, St. Louis, MO, USA). Histopathologic analysis of inflammatory cells in H&E stained lung sections from five mice was performed in a blinded fashion using a semi-quantitative scoring system as previously described 16, 23 . Peribronchiolar inflammation were scored as follows: 0, normal; 1, few cells; 2, a ring of inflammatory cells one cell layer deep; 3, a ring of inflammatory cells two to four cells deep; and 4, a ring of inflammatory cells of more than four cells deep. Morphometric analysis of PAS stained sections was performed by quantifying PAS pixels per μm length using the Image J software. At least six randomly selected fields in each section were assessed blindly by an expert pathologist. Airway hyper-responsiveness. In response to different concentrations of methacholine, the airway resistance was measured invasively in pentobarbital sodium-anesthetized mice 24 h after the last OVA challenge as previously described 24 , using a respiratory function instrument (AniRes2005, BioMedical Supply Co., Ltd., Beijing, China).
Statistical analysis.
All data were expressed as mean ± SD and analyzed using the Student's two-tailed t-test or one-way analysis of variance (ANOVA) test followed by LSD's multiple comparison test. A value of P < 0.05 was considered statistically significant.
Results
Overexpression of IL-28B inhibited OVA-induced allergic asthma in mice. IL-28A has been shown to inhibit OVA-induced allergic airway diseases 24 . However, the role of IL-28B in these diseases has never been investigated. In this study, we overexpressed IL-28B in mice by hydrodynamic tail vein injections of 20 µg plasmids plive-IL-28B or plive-vector and PBS one day prior to OVA sensitization, and then the mice were sensitized and challenged with OVA as indicated in Fig. 1A . Samples were collected and analyzed 24 h after the last challenge. The results indicated that IL-28B was stably overexpressed in serum and BALF for at least 17 days ( Fig. 1B  and C) . Importantly, compared with control group, overexpression of IL-28B significantly inhibited OVA-induced allergic asthma as evidenced by the marked decrease in the numbers of eosinophils, neutrophils and lymphocytes as well as IgE production and airway resistance in the mouse lung ( Fig. 1D-H) . Consistently, the reduced leukocyte infiltration was also observed in the peribronchial areas (Fig. 1I ). In addition, overexpression of IL-28B greatly suppressed OVA-induced goblet cell hyperplasia and mucus hypersecretion in airway epithelium (Fig. 1J) . These data suggest that IL-28B plays an inhibitory role in OVA-induced airway inflammation.
Overexpression of IL-28B increased the number and frequency of NK cells in OVA-challenged mouse lungs.
In order to determine the mechanisms whereby IL-28B inhibited OVA-induced airway inflammation, we examined the numbers of lymphocytes in IL-28B-overexpressed lungs after OVA challenge. The results showed that IL-28B had no effects on the numbers of T (CD4+, CD8+) cells, B cells, NKT cells γδT cells ( Fig. 2A-C) as well as macrophages and Dendritic cells (Fig. S1A,B and D) , but significantly increased the number and percentage of NK cells in OVA-challenged lungs (Fig. 2D ), suggesting the possible involvement of NK cells in inhibiting OVA-induced airway inflammation.
NK cells mediated IL-28B-suppressed airway inflammation.
In order to determine if NK cells are involved in IL-28-suppressed airway inflammation, NK cells were depleted in mice by intraperitoneal injections of 50 µl AsGM1 antibody one day prior to the initial OVA challenge, and rabbit IgG was used as control (Fig. 3A) . As shown in Fig. 3B -D, AsGM1 antibody effectively depleted NK cells for at least 4 days, but has no significant effect of anti-ASGM1 treatment on the numbers of Macrophages and Dendritic cells (Fig. S1A,C and E ), suggesting the high specificity of anti-ASGM1 treatment. Flow cytometry and cell counting assays indicated that AsGM1 injection significantly increased the frequency and numbers of eosinophils, neutrophils, and lymphocytes in BALF as well as IgE production and airway resistance in the mouse lung compared with control group (Fig. 4A-E) , as well as greatly promoting the leukocyte infiltration in the peribronchial areas (Fig. 4F ). Furthermore, AsGM1 injection markedly enhanced IL-28B-suppressed goblet cell hyperplasia and mucus hypersecretion in airway epithelium (Fig. 4G) . These data demonstrate that IL-28B inhibition of OVA-induced airway inflammation is NK cell-dependent.
IL-28B inhibition of OVA-induced airway inflammation depended on IFN-γ.
In order to further investigate the mechanism by which NK cells mediate IL-28B-inhibited airway inflammation induced by OVA, NK cell-produced cytokines were examined. The results showed that IL-28B overexpression resulted in significant increase in the number of IFN-γ-producing NK cells (Fig. 5A ). IFN-γ is an important cytokine that inhibits Th2-mediated inflammatory response 25 , suggesting that IFN-γ might mediate IL-28B-or NK cell-inhibited Th2 inflammatory response 26 . We overexpressed IL-28B in IFN-γ−/− mice by tail vein injections followed by OVA sensitization and challenge, and found IL-28B overexpression had no effects on the numbers of eosinophils, neutrophils, and lymphocytes in BALF as well as IgE production and airway resistance in the mouse lung compared with control plasmid or PBS group (Fig. 5B-F) . Consistent with this finding, there was no significant changes in the degree of leukocyte infiltration into the peribronchial areas, airway goblet cell hyperplasia and mucus hypersecretion (Fig. 5G,H) . These data demonstrate that IFN-γ is essential for IL-28B-suppressed airway inflammation. Discussion IFN-λ, as a member of IFN family, includes IL-28A, IL-28B and IL-29. It regulates both innate and adaptive immunity, and has potential antiviral and anticancer properties 27 . IL-28A can inhibit allergic airway inflammation through regulating DC function 16 . However, the role of IL-28B in inhibiting allergic airway inflammation remains unknown. In the present study, we demonstrate that IL-28B can suppress OVA-induced allergic airway inflammation via promoting NK cell polarization.
NK cells are a distinct type of innate lymphocytes analogous to the cytotoxic T cells of the adaptive immune systems. They play a critical role in combating allergen-or virus-induced respiratory diseases like asthma 28 . IL-28 acts directly on NK cells that express IL-28R to regulate NK cell effector functions and enhance IFN-γ production 20, 27 . IFN-γ-producing NK cells then enter local lymph nodes to interact with DCs, leading to DC activation and IL-27 secretion. IL-27 further induces NK cell to produce IFN-γ which inhibits Th2 and Th17 polarization, through a positive feedback mechanism 29, 30 . NK cell subsets NK1 and NK2 have been found to differently regulate expression of immunity-related genes like NK receptor and IgE, during inflammatory processes 31 .
In this study, we indicate that IL-28B overexpression effectively decreases the frequencies and numbers of inflammatory effector cells including eosinophils, neutrophils and lymphocytes in BALF in OVA-induced mouse asthma model (Fig. 1) . IL-28B appears to modulate the activation of pulmonary epithelium that also expresses IL-28R, because IL-28B overexpression reduces airway goblet cell hyperplasia and subsequent mucus production ( Fig. 1) . Interestingly, IL-28B exerts no effects on the frequencies and numbers of T and B cells in lungs of asthmatic mice, suggesting that other cell type is involved in IL-28B inhibition of the OVA-induced airway inflammation. Our data show that NK cells may be the right ones as evidenced by IL-28B-induced increases in frequency and number of NK cells, especially those of IFN-γ-producing NK1 cells (Figs. 2,3 and 4 ). NK1 cell polarization that increases IFN-γ secretion probably play an important role in IL-28B-suppressed airway inflammation. Indeed, both NK cell depletion by ASGM1 and IFN-γ knockout reverses the inhibitory effect of IL-28B on OVA-induced allergic asthma (Figs. 4 and 5). Our findings are consistent with the previous studies that IFN-γ is responsible for allergic airway inflammation and mucus secretion 32, 33 . In addition, patients with asthma exhibit reduced NK cell-mediated IFN-γ production which weakens the capabilities of promoting DC maturation and killing immature DCs, whereas NK2 cell frequency is enhanced [34] [35] [36] , indicating the possible involvement of NK cells in human asthma. These findings are further confirmed by our present study in a mouse model of OVA-induced allergic asthma.
However, the true roles of NK cells in the regulation of airway inflammation still remain controversial. It was reported that NK cell depletion in vivo abrogated development of allergic airway inflammation 37 . The opposite functions of NK cells in allergic airway diseases may be likely due to the different experimental conditions such as strength and duration of allergen sensitization and challenge, which may lead to the diverse NK cell activities in inflammatory responses.
In summary, our study identifies IL-28B as a novel negative regulator of OVA-induced allergic airway inflammation like asthma, suggesting a new role of IL-28B in adaptive immunity. Therefore, IL-28B may serve as a potential therapeutic agent for effective intervention of allergic asthma via promoting NK1 cell polarization and IFN-γ production.
